In Venture Capital Slump, Genomic Sector in 2001 Blasts Past Last Year s Growth | GenomeWeb

NEW YORK, Oct. 2 – Young, private genomic companies in the US anxious about a constricting venture capital market can breathe easy.

Despite sharp drops in the stock market, a receding overall venture capital tide, and the economic uncertainty brought on by the terrorist assault on the US three weeks ago, industry analysts believe that the private equity environment for early-stage genomic companies remains robust, has been outperforming the overall VC market, and shows signs of growth in the new year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.